All In Biotech

Drug Trial Radar · NCT06594146

Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP)

A Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Initial Efficacy of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia

Last checked: Nov 19, 2026Latest source record: Apr 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

62

Actual

Start

Nov 11, 2024

Primary completion

Dec 30, 2025

Study completion Dec 30, 2025

Sponsor

Lead sponsor
Keymed Biosciences Co.LtdIndustry
Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and initial efficacy of CM313 (SC) injection in patients with primary immune thrombocytopenia.

Conditions

  • Primary Immune Thrombocytopenia

Interventions

  • CM313 injectionBiological

    CM313

  • placeboOther

    placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse eventTime frame: Up to Week 16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institute of Hematology & Blood Diseases Hospital

    Tianjin, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.